
Dear Readers, There are two notable updates in this week’s blog. First, The U.S. Food and Drug Administration’s (FDA) Advisory Committee decided that it could not recommend approval of Amyvid™ (florbetapir) at this time based on the currently available data (13-3); but, voted unanimously (16-0) to recommend approval of Amyvid conditional on specialized training being instituted for the medical professionals who would administer it. They must train readers in a consistent technique, and then re-evaluate [...]




